Janux Therapeutics (JANX) Depreciation and Depletion (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Depreciation and Depletion of $469000.0 for Q1 2026, down 9.63% year-over-year from $519000.0 in Q1 2025, and little changed quarter-over-quarter from $468000.0 in Q4 2025.
Janux Therapeutics (JANX) Depreciation and Depletion (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Depreciation and Depletion for 7 consecutive years, with $469000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation and Depletion fell 9.63% year-over-year to $469000.0; the TTM figure through Mar 2026 stood at $2.0 million (down 3.32% YoY), while the FY2025 annual figure was $2.0 million, down 1.5% from the prior year.
- Depreciation and Depletion was little changed at $469000.0 in Q1 2026 per JANX's latest filing, from $468000.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $541000.0 in Q2 2025 and bottomed at $81000.0 in Q1 2022.
- Historically, Depreciation and Depletion has averaged $432588.2 across 5 years, with a median of $500000.0 in 2023.
- Annual changes were most pronounced in 2022 — Depreciation and Depletion soared 822.22% — and 2026, when it dropped 9.63%.
- Janux Therapeutics' Depreciation and Depletion stood at $403000.0 in 2022, then surged by 31.76% to $531000.0 in 2023, then retreated by 3.58% to $512000.0 in 2024, then retreated by 8.59% to $468000.0 in 2025, then grew by 0.21% to $469000.0 in 2026.
- Business Quant data shows JANX's Depreciation and Depletion at $469000.0 in Q1 2026, $468000.0 in Q4 2025, and $501000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 38.91 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 463,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 463,000.00 |
| Jun 30, 2026 | 463,000.00 |
| Mar 31, 2026 | 469,000.00 |
| Mar 31, 2026 | 469,000.00 |
| Dec 31, 2025 | 468,000.00 |
| Dec 31, 2025 | 468,000.00 |
| Sep 30, 2025 | 501,000.00 |
| Sep 30, 2025 | 501,000.00 |
| Jun 30, 2025 | 541,000.00 |
| Jun 30, 2025 | 541,000.00 |
| Mar 31, 2025 | 519,000.00 |
| Mar 31, 2025 | 519,000.00 |
| Dec 31, 2024 | 512,000.00 |
| Dec 31, 2024 | 512,000.00 |
| Sep 30, 2024 | 510,000.00 |
| Sep 30, 2024 | 510,000.00 |
| Jun 30, 2024 | 506,000.00 |
| Jun 30, 2024 | 506,000.00 |
| Mar 31, 2024 | 532,000.00 |
| Mar 31, 2024 | 532,000.00 |